Search Tag: biopharmaceutical

ICU Management

Getinge-completes-acquisition-of-high-purity-new-england-inc

2023 04 Oct

Getinge has completed the previously announced acquisition of 100% of the shares in High Purity New England, Inc.   On May 31, 2023, Getinge announced an agreement to acquire High Purity New England, Inc., a leading US-based company in the fast-growing areas of custom single-use solutions for bioprocessing applications.   All conditions...Read more

Executive Health Management

Nuvalent-appoints-michael-l-meyers-md-phd-to-board-of-directors

2022 06 Oct

Nuvalent, Inc, a clinical-stage biopharmaceutical company focused on creating  precisely  targeted therapies for clinically proven kinase targets in cancer announced the appointment of  Michael L. Meyers , M.D., Ph.D., to its Board of Directors. An experienced drug developer and medical oncologist who has contributed to the successful development and...Read more

Executive Health Management

Robert-s-langer-scd-joins-bexson-biomedical-its-scientific-advisory-board

2022 20 Sep

Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the $189 billion small molecule injectable market and enabling home health solutions announced the appointment of Robert S. Langer ScD, MIT David H. Koch Institute Professor and Co-founder of Moderna, to its Scientific Advisory Board (SAB). "We are excited to have Dr. Langer...Read more

Executive Health Management

Everest-medicines-announces-the-departure-of-ceo-kerry-blanchard

2022 26 Aug

Everest Medicines , a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets announced that Dr. Kerry Blanchard has resigned as Chief Executive Officer and as a member of the Board of Directors, effective immediately. He will remain as an advisor...Read more

Pharmacy Management

Biosimilars-billions-in-sales-and-savings-by-2020

2014 01 Oct

According to new research from Thomson Reuters Bioworld, there are more than 700 follow-on biologic therapies currently in development. The new therapies are expected to generate approximately $100 billion in sales by the end of this decade. These projections demonstrate that the biopharmaceutical development industry is rapidly growing with...Read more